Previous O
studies O
evaluated O
the O
tolerance O
of O
nimesulide B
and O
paracetamol B
in O
subjects O
with O
cutaneous O
, O
respiratory O
and O
anaphylactoid O
reactions O
induced O
by O
nonsteroidal B
anti I
- I
inflammatory I
drugs I
( O
NSAIDs B
) O
. O

( B
RS I
) I
- I
1 I
- I
aminoindan I
- I
1 I
, I
5 I
- I
dicarboxylic I
acid I
( O
AIDA B
; O
0 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
potent O
and O
selective O
mGluR1 O
antagonist O
, O
or O
( B
2R I
, I
4R I
) I
- I
4 I
- I
aminopyrrolidine I
- I
2 I
, I
4 I
- I
dicarboxylate I
( O
2R B
, I
4R I
- I
APDC I
; O
7 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
selective O
group O
II O
agonist O
, O
was O
injected O
bilaterally O
into O
the O
striatum O
of O
haloperidol B
- O
treated O

In O
contrast O
, O
2R B
, I
4R I
- I
APDC I
injections O
were O
ineffective O
. O

The O
liver O
levels O
of O
beta O
- O
oxidation O
metabolites O
of O
VPA B
were O
decreased O
by O
day O
14 O
, O
while O
the O
levels O
of O
4 B
- I
ene I
- I
VPA I
and O
( O
E O
) O
- O
2 B
, I
4 I
- I
diene I
- I
VPA I
were O
not O
elevated O
throughout O
the O
study O
. O

Although O
3 B
, I
4 I
- I
methylenedioxymethamphetamine I
( O
MDMA B
or O
ecstasy B
) O
has O
been O
shown O
to O
damage O
brain O
serotonin B
( O
5 B
- I
HT I
) O
neurons O
in O
animals O
and O
possibly O
humans O
, O
little O
is O
known O
about O
the O
long O
- O
term O
consequences O
of O
MDMA B
- O
induced O
5 B
- I
HT I
neurotoxic O
lesions O
on O
functions O
in O
which O
5 B
- I
HT I
is O
involved O
, O
such O
as O
cognitive O
function O
. O

Detection O
of O
abnormal O
cardiac O
adrenergic O
neuron O
activity O
in O
adriamycin B
- O
induced O
cardiomyopathy O
with O
iodine B
- I
125 I
- I
metaiodobenzylguanidine I
. O

The O
serotonin B
- O
1A O
receptor O
agonist O
, O
8 B
- I
OH I
- I
DPAT I
, O
induced O
a O
significant O
disruption O
of O
PPI O
in O
all O
groups O
. O

An O
extremely O
rare O
case O
of O
delusional O
parasitosis O
in O
a O
chronic O
hepatitis O
C O
patient O
during O
pegylated B
interferon I
alpha I
- I
2b I
and O
ribavirin B
treatment O
. O

We O
present O
a O
49 O
- O
year O
- O
old O
woman O
who O
developed O
a O
delusional O
parasitosis O
during O
treatment O
with O
pegylated B
interferon I
alpha I
- I
2b I
weekly O
and O
ribavirin B
. O

All O
the O
complaints O
disappeared O
after O
stopping O
pegylated B
interferon I
alpha I
- I
2b I
and O
reappeared O
after O
restarting O
it O
. O

BACKGROUND O
: O
Unfractionated B
heparin I
sodium I
( O
UFH B
) O
or O
low B
- I
molecular I
weight I
heparin I
( O
LMWH O
) O
is O
used O
in O
anticoagulant O
protocols O
at O
several O
institutions O
to O
prevent O
thrombosis O
after O
liver O
transplantation O
. O

The O
hemodynamic O
effects O
of O
captopril B
and O
other O
angiotensin B
- I
converting I
enzyme I
inhibitors I
may O
be O
mediated O
by O
the O
endogenous O
opioid O
system O
. O

The O
condition O
is O
treated O
with O
intravenous O
thyroxine B
( O
T4 B
) O
or O
intravenous O
tri B
- I
iodo I
- I
thyronine I
( O
T3 B
) O
. O

In O
spontaneously O
hypertensive O
, O
stroke O
- O
prone O
rats O
, O
microinjection O
of O
methyldopa B
into O
the O
area O
of O
the O
midline O
B3 O
serotonin B
cell O
group O
in O
the O
ventral O
medulla O
caused O
a O
potent O
hypotension O
of O
30 O
- O
40 O
mm O
Hg O
, O
which O
was O
maximal O
2 O
- O
3 O
h O
after O
administration O
and O
was O
abolished O
by O
the O
serotonin B
neurotoxin O
5 B
, I
7 I
- I
dihydroxytryptamine I
( O
5 B
, I
7 I
- I
DHT I
) O
injected O
intracerebroventricularly O
. O

In O
spontaneously O
hypertensive O
, O
stroke O
- O
prone O
rats O
, O
microinjection O
of O
methyldopa B
into O
the O
area O
of O
the O
midline O
B3 O
serotonin B
cell O
group O
in O
the O
ventral O
medulla O
caused O
a O
potent O
hypotension O
of O
30 O
- O
40 O
mm O
Hg O
, O
which O
was O
maximal O
2 O
- O
3 O
h O
after O
administration O
and O
was O
abolished O
by O
the O
serotonin B
neurotoxin O
5 B
, I
7 I
- I
dihydroxytryptamine I
( O
5 B
, I
7 I
- I
DHT I
) O
injected O
intracerebroventricularly O
. O

However O
, O
intraspinal O
injection O
of O
5 B
, I
7 I
- I
DHT I
to O
produce O
a O
more O
selective O
lesion O
of O
only O
descending O
serotonin B
projections O
in O
the O
spinal O
cord O
did O
not O
affect O
this O
hypotension O
. O

Further O
, O
5 B
, I
7 I
- I
DHT I
lesion O
of O
serotonin B
nerves O
travelling O
in O
the O
median O
forebrain O
bundle O
, O
one O
of O
the O
main O
ascending O
pathways O
from O
the O
B3 O
serotonin B
cells O
, O
did O
not O
affect O
the O
fall O
in O
blood O
pressure O
associated O
with O
a O
midline O
B3 O
serotonin B
methyldopa B
injection O
. O

Adverse O
interaction O
between O
beta B
- I
adrenergic I
blocking I
drugs I
and O
verapamil B
- O
- O
report O
of O
three O
cases O
. O

Three O
patients O
with O
ischaemic O
heart O
disease O
developed O
profound O
cardiac O
failure O
, O
hypotension O
and O
bradycardia O
during O
combined O
therapy O
with O
verapamil B
and O
beta B
- I
adrenergic I
blocking I
drugs I
. O

Simultaneously O
administration O
of O
beta B
- I
adrenergic I
blocking I
drugs I
and O
verapamil B
may O
result O
in O
profound O
adverse O
interactions O
and O
should O
only O
be O
administered O
with O
great O
caution O
. O

Treatment O
of O
ifosfamide B
- O
induced O
urothelial O
toxicity O
by O
oral O
administration O
of O
sodium B
2 I
- I
mercaptoethane I
sulphonate I
( O
MESNA B
) O
to O
patients O
with O
inoperable O
lung O
cancer O
. O

The O
protective O
effect O
of O
oral O
administration O
of O
the O
thiol B
compound O
sodium B
2 I
- I
mercaptoethane I
sulphonate I
( O
MESNA B
) O
against O
urothelial O
toxicity O
induced O
by O
ifosfamide B
( O
IF B
) O
was O
tested O
in O
a O
group O
of O
45 O
patients O
with O
inoperable O
lung O
cancer O
under O
treatment O
with O
IF B
( O
2250 O
mg O
/ O
m2 O
on O
days O
2 O
- O
5 O
) O
as O
part O
of O
a O
polychemotherapy O
regimen O
repeated O
in O
a O
4 O
- O
week O
cycle O
. O

In O
normal O
conscious O
rats O
investigated O
by O
continuous O
cystometry O
, O
intravesically O
instilled O
prostaglandin B
( I
PG I
) I
E2 I
facilitated O
micturition O
and O
increased O
basal O
intravesical O
pressure O
. O

The O
safety O
and O
efficacy O
of O
combination O
N B
- I
butyl I
- I
deoxynojirimycin I
( O
SC B
- I
48334 I
) O
and O
zidovudine B
in O
patients O
with O
HIV O
- O
1 O
infection O
and O
200 O
- O
500 O
CD4 O
cells O
/ O
mm3 O
. O

We O
conducted O
a O
double O
- O
blind O
, O
randomized O
phase O
II O
study O
to O
evaluate O
the O
safety O
and O
activity O
of O
combination O
therapy O
with O
N B
- I
butyl I
- I
deoxynojirimycin I
( O
SC B
- I
48334 I
) O
( O
an O
alpha O
- O
glucosidase O
I O
inhibitor O
) O
and O
zidovudine B
versus O
zidovudine B
alone O
. O

They O
were O
then O
treated O
chronically O
with O
L B
- I
DOPA I
/ I
benserazide I
50 O
/ O
12 O
. O
5 O
mg O
/ O
kg O
given O
orally O
daily O
for O
2 O
months O
. O

Infusion O
of O
the O
central O
nervous O
system O
alpha2 B
- I
adrenergic I
receptor I
agonist I
clonidine B
also O
resulted O
in O
a O
greater O
reduction O
in O
MAP O
in O
both O
groups O
of O
SHR O
that O
were O
fed O
the O
high O
( O
compared O
with O
the O
basal O
) O
sodium B
chloride I
diet O
. O

5 B
, I
7 I
- I
dichlorokynurenic I
acid I
( O
5 B
, I
7 I
- I
DCKA I
) O
, O
a O
selective O
glycine B
site O
antagonist O
, O
injected O
in O
doses O
of O
2 O
. O
5 O
and O
4 O
. O
5 O
microg O
/ O
0 O
. O
5 O
microl O
bilaterally O
, O
into O
the O
rostral O
region O
of O
the O
striatum O
, O
decreased O
both O
the O
haloperidol B
- O
induced O
muscle O
rigidity O
( O
MMG O
) O
and O
the O
enhanced O
electromyographic O
activity O
( O
EMG O
) O
. O

5 B
, I
7 I
- I
DCKA I
injected O
bilaterally O
in O
a O
dose O
of O
4 O
. O
5 O
microg O
/ O
0 O
. O
5 O
microl O
into O
the O
intermediate O
- O
caudal O
region O
of O
the O
striatum O
of O
rats O
not O
pretreated O
with O
haloperidol B
had O
no O
effect O
on O
the O
muscle O
tone O
. O

